What question did this study set out to answer?

To investigate the effects of phosphodiesterase type 5 (PDE5) inhibitors on right ventricle (RV) contractility and afterload in patients with RV hypertrophy.

July 2, 2007CirculationOpen Access

Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility

View Full Paper

Ask AI

Bookmark

Why the study?

Do PDE5 inhibitors improve RV inotropy and decrease RV afterload in hypertrophied human right ventricles?

Population

Hypertrophied human right ventricle / diseases affecting the RV (e.g., pulmonary arterial hypertension)

Design

Preclinical

Authors

JNJayan NagendranCardiac Surgery SAStephen L. ArcherGeneral Cardiology DSDaniel SolimanUniversity of the Sciences

Discussion

Member takes

Implication

Supports human RV trials; leaves open translation from animal models to hypertrophied ventricles.

Key Points

To investigate the effects of phosphodiesterase type 5 (PDE5) inhibitors on right ventricle (RV) contractility and afterload in patients with RV hypertrophy.
Assessed the expression of PDE5 in hypertrophied human right ventricles.
Evaluated the effects of acute PDE5 inhibition on RV contractility and afterload.
Compared systemic hemodynamics during treatment.
PDE5 inhibition significantly increased RV inotropy (p<0.05).
RV afterload decreased without significant changes in systemic hemodynamics (p=0.08).
These findings suggest potential therapeutic implications for treating pulmonary arterial hypertension.

Structured PICO

Do PDE5 inhibitors improve RV inotropy and decrease RV afterload in hypertrophied human right ventricles?

Population

Hypertrophied human right ventricle / diseases affecting the RV (e.g., pulmonary arterial hypertension)

Intervention

PDE5 inhibitors (acute inhibition of Phosphodiesterase Type 5)

Outcome

RV contractility (inotropy) and RV afterloadsurrogate

PDE5 inhibitors improve right ventricular contractility and reduce afterload without systemic effects, supporting their use in right ventricular diseases like pulmonary arterial hypertension.

Cite This Study

Nagendran et al. (2007) studied this question.

synapsesocial.com/papers/69b31e4c52eef3fac5b3f56e https://doi.org/10.1161/circulationaha.106.655266

View Full Paper

Ask AI

Bookmark

Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider